# Neoadjuvant Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer

> **NCT07104149** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital of Zhengzhou University** · enrollment: 29 (estimated)

## Conditions studied

- Female, Age ≥ 18 Years Old
- No Previous Systemic Treatment for the Current Disease, Including Surgery, Antitumor Radiochemotherapy/Immunotherapy
- ECOG Score of 0-1
- Histologically Confirmed Cervical Cancer, FIGO Stage IB3, IIA2, IIB, IIIC, and Assessed by the Researcher as Resectable Lesion
- Sufficient Organ Function
- The Result of the Urine or Serum Pregnancy Test for the Subject is Negative
- Subjects Should Take Contraceptive Measures
- Locally Advanced Cervical Cancer
- Expected Survival Time >6 Months

## Interventions

- **DRUG:** Cadonilimab combined with cisplatin

## Key facts

- **NCT ID:** NCT07104149
- **Lead sponsor:** The First Affiliated Hospital of Zhengzhou University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-10
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-06-30
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2025-08-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07104149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07104149, "Neoadjuvant Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07104149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*